Hepatitis B virus (HBV) has a narrow host range, mainly infecting hominoids. A new study reveals the structural differences in the liver cell receptor (NTCP) between humans and monkeys, explaining why HBV infects humans but not monkeys. This marks a significant medical breakthrough, by identifying new molecular targets for anti-HBV drug development for treating hepatitis B, a disease that places a tremendous burden on the global economy.
Read more …The viral puzzle of why humans are susceptible to hepatitis B virus, but monkeys are not
A new approach could herald a shift in the way we use antibiotics. By attacking the pathogen's unique and hidden metabolic 'vulnerabilities,' researchers offers a new tool in the global challenge to counteract antibiotic resistance and uncover similar combination therapies for other diseases.
Read more …Combo-drug treatment to combat Melioidosis